A5071732733- Rheumatoid Arthritis Research and Therapies
- Pregnancy and Medication Impact
- Reproductive System and Pregnancy
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Viral Infections and Immunology Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Biosimilars and Bioanalytical Methods
- Microscopic Colitis
- Lymphoma Diagnosis and Treatment
- Endometriosis Research and Treatment
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Esophagitis
- Pharmaceutical studies and practices
- Inflammatory Bowel Disease
- Spondyloarthritis Studies and Treatments
- Platelet Disorders and Treatments
- Facial Nerve Paralysis Treatment and Research
- Systemic Sclerosis and Related Diseases
- Autoimmune Bullous Skin Diseases
- Child and Adolescent Health
- Proteoglycans and glycosaminoglycans research
- Inflammasome and immune disorders
- Advanced Drug Delivery Systems
- Pregnancy-related medical research
German Rheumatism Research Centre
2014-2024
Charité - Universitätsmedizin Berlin
2017-2024
MRC Epidemiology Unit
2017
Université de franche-comté
2006-2007
Inserm
2006
Objective To investigate the risk of developing lower intestinal perforations (LIPs) in patients with rheumatoid arthritis (RA) treated tocilizumab (TCZ). Methods In 13 310 RA observed German biologics register R heumatoid A rthritis: O b servation Bi ologic T herapy, 141 serious gastrointestinal events possibly associated were reported until 31 October 2015. All validated independently by two physicians, blinded for treatment exposure. Results 37 LIPs (32 colon/sigma) 53 972 patient years...
To estimate the effects of Janus kinase inhibitors (JAKi), tumour necrosis factor (TNFi), other biologic(b) or conventional synthetic(cs) disease-modifying antirheumatic drugs (DMARDs) on risk major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA).Cohort study analysing episodes DMARD-treatment initiated between January 2017 and April 2022 biologics register Rheumatoid Arthritis: Observation Biologic Therapy. Incidence rates (IRs) per 100 patient-years 95% CIs...
There is an urgent need for robust data on the trajectories and outcomes of pregnancies in women with inflammatory rheumatic diseases (IRD). In particular when rare or are to be investigated, collaborative approaches required. However, joint analyses often limited by heterogeneity different sources.To facilitate future research collaboration, a European League Against Rheumatism (EULAR) Task Force defined core set minimum items collected pregnancy registries rheumatology covering period...
Objectives To investigate the impact of disease activity and treatment with disease-modifying antirheumatic drugs (DMARDs) on all-cause mortality in patients rheumatoid arthritis prevalent interstitial lung (RA-ILD). Methods Patients RA-ILD were selected from biologics register Rheumatoid Arthritis: Observation Biologic Therapy (RABBIT). Using time-varying Cox regression, association between clinical measures was investigated. The DMARDs analysed by (1) regression considering cumulative...
The aim was to estimate the impact of individual risk factors and treatment with various disease-modifying antirheumatic drugs (DMARDs) on incidence myocardial infarction (MI) in patients rheumatoid arthritis (RA). We analysed data from 11,285 RA, enrolled prospective cohort study RABBIT, at start biologic (b) or conventional synthetic (cs) DMARDs. A nested case–control conducted, defining MI during follow-up as cases. Cases were matched 1:1 control based age, sex, year enrolment five...
<h3>Background:</h3> Counselling patients with rheumatic and musculoskeletal diseases (RMD) in the phase of reproduction, pregnancy lactation is a challenging task. In women, potential risk drug therapy needs to be weighed against untreated maternal RMD associated risks for mother child. men, safety antirheumatic drugs regard fertility pregnancy/offspring outcomes considered. The first EULAR points consider (PtC) use before pregnancy, during published 2016 have been widely used [1]....
Objective In the general population, incidence of stroke is increased following other serious events and hospitalisation. We investigated impact adverse on risk in patients with rheumatoid arthritis (RA), taking factors treatment into account. Methods Using data German biologics register RABBIT (Rheumatoid Arthritis: Observation Biologic Therapy) 12354 RA, rates (IRs) for were using multi-state Cox proportional hazard models. addition, a nested case–control study, all matched 1:2 to...
Abstract Background The collaborative initiative of the European Network Pregnancy Registers in Rheumatology (EuNeP) aims to combine data available nationwide pregnancy registers increase knowledge on outcomes women with inflammatory rheumatic diseases (IRD) and drug safety during lactation. objective this study was describe similarities differences member registers. Methods From all registers, information about their structure design collected, as well which parameters regarding...
The effectiveness of TNF inhibitors in RA has been shown to be affected by obesity. No such effect found for abatacept and rituximab, while tocilizumab results are ambiguous. Additionally, it remains unresolved whether sex is an modifier We investigated the impact obesity on drug conventional synthetic or biologic DMARDs, taking into account potential sex-specific differences.
Objective To investigate outcome and course of pregnancies in women with axial spondyloarthritis (axSpA) a pooled data analysis pregnancy registries rheumatology. Methods Prospectively followed axSpA, fulfilling ASAS classification criteria for whom was reported, were eligible the analysis. Anonymised four pooled. Rates adverse outcomes calculated. Systemic inflammation, disease activity treatment patterns tumour necrosis factor inhibitor (TNFi) before, during after analysed. Results In...
To evaluate the risk of malignancy (overall, breast, lung, and lymphoma) in patients with rheumatoid arthritis treated abatacept, conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs), other biologic/targeted (b/ts)DMARDs clinical practice. Four international observational data sources were included: ARTIS (Sweden), RABBIT (Germany), FORWARD (USA), BC (Canada). Crude incidence rates (IRs) per 1000 patient-years exposure 95% confidence intervals (CIs) for a event...
Low-molecular-weight heparins (LMWH) have been shown to be efficient in the treatment of inflammatory bowel disease (IBD). Parenteral heparin therapy, however, may cause hemorrhagic adverse effects. To reduce this risk, epithelial LMWH delivery combination with a system ensuring selective drug release inflamed tissue was tested here. Enoxaparin loaded microspheres (MS) were administered orally male BALB mice suffering from pre-existing experimental colitis, whereas control groups received...
In pharmacoepidemiology, robust data are needed to judge the impact of drug treatment on pregnancy, pregnancy outcomes and breast-fed infants. As pregnant breastfeeding women usually excluded from randomised clinical trials, observational studies required. One those sources registers specifically developed focus certain diseases or disease groups. The German Rhekiss register investigates pregnancies in with chronic inflammatory rheumatic (IRD). is a nationwide, multicentre, longitudinal...
Background In 2021, the European and US-American regulatory agencies EMA FDA issued warnings about cardiovascular (CV) safety of Janus kinase inhibitor (JAKi) tofacitinib required changes in labelling. These actions were based on results post-authorisation trial Oral Surveillance (1) . Objectives To analyse major events (MACE) under treatment with JAKi, tumor necrosis factor inhibitors (TNFi) or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs - bionaive) patients...
: To evaluate risk of infections requiring hospitalization (HIs) and opportunistic (OIs), including tuberculosis, in patients with rheumatoid arthritis (RA) treated abatacept versus conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) other biologic/targeted (b/ts) DMARDs. Five international observational data sources were used: two biologic registries (Sweden, Germany), a disease registry (USA) healthcare claims databases (Canada, USA). Crude incidence rates (IRs) per...